Skip to content
2000
Volume 10, Issue 1
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Many therapeutic reagents for hepatitis B virus infection have established efficacy in goals such as alanine aminotransferase normalization, hepatitis B virus DNA suppression, HBeAg seroconversion, histological improvement, and reduce disease progression. However, it is not established that the efficacy of these reagents for the long-term survival and prevention of hepatocellular carcinoma although recent meta-analyses have also shown antiviral therapy to be efficacious. This article reviews the current status and innovative new options for antiviral therapy for hepatitis B and also discusses the various mechanisms of action for each drug, the results of clinical studies for each therapy, and the problems yet to be solved with respect to hepatitis B treatment.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955710791112613
2010-01-01
2025-09-05
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955710791112613
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test